Zura Bio Limited (ZURA) is a Biotechnology company in the Healthcare sector, currently trading at $5.72. It has a SharesGrow Score of 59/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is ZURA = $15 (+162.2% upside).
Valuation: ZURA trades at a trailing Price-to-Earnings (P/E) of -5.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.75.
Net income is $99M (loss), growing at -631.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $0 against $102M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 9.05 (strong liquidity). Debt-to-assets is 0%. Total assets: $114M.
Analyst outlook: 6 / 7 analysts rate ZURA as buy (86%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).
